NCT06222671View on ClinicalTrials.gov

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

September 22, 2025

Study Completion Date

November 30, 2025

Conditions
Axial Spondyloarthritis
Interventions
DRUG

608

608 subcutaneous (SC) injection.

DRUG

608

608 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Trial Locations (6)

100730

RECRUITING

Site 01, Beijing

RECRUITING

Site 03, Beijing

210008

RECRUITING

Site 04, Nanjing

400010

RECRUITING

Site 05, Chongqing

450052

RECRUITING

Site 02, Zhengzhou

518020

NOT_YET_RECRUITING

Site 06, Shenzhen

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY